Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
44.36
-0.01 (-0.02%)
At close: Dec 5, 2025, 4:00 PM EST
44.49
+0.13 (0.28%)
After-hours: Dec 5, 2025, 7:28 PM EST
Exelixis Employees
Exelixis had 1,147 employees as of December 31, 2024. The number of employees decreased by 163 or -12.44% compared to the previous year.
Employees
1,147
Change (1Y)
-163
Growth (1Y)
-12.44%
Revenue / Employee
$1,994,959
Profits / Employee
$591,023
Market Cap
11.94B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,147 | -163 | -12.44% |
| Dec 31, 2023 | 1,310 | 87 | 7.11% |
| Dec 31, 2022 | 1,223 | 269 | 28.20% |
| Dec 31, 2021 | 954 | 181 | 23.42% |
| Dec 31, 2020 | 773 | 156 | 25.28% |
| Dec 31, 2019 | 617 | 133 | 27.48% |
| Dec 31, 2018 | 484 | 112 | 30.11% |
| Dec 31, 2017 | 372 | 85 | 29.62% |
| Dec 31, 2016 | 287 | 172 | 149.57% |
| Dec 31, 2015 | 115 | 17 | 17.35% |
| Dec 31, 2014 | 98 | -129 | -56.83% |
| Dec 31, 2013 | 227 | 53 | 30.46% |
| Dec 31, 2012 | 174 | -26 | -13.00% |
| Dec 31, 2011 | 200 | -183 | -47.78% |
| Dec 31, 2010 | 383 | -293 | -43.34% |
| Dec 31, 2009 | 676 | 0 | - |
| Dec 31, 2008 | 676 | -59 | -8.03% |
| Dec 31, 2007 | 735 | 84 | 12.90% |
| Dec 31, 2006 | 651 | 101 | 18.36% |
| Dec 31, 2005 | 550 | 33 | 6.38% |
| Dec 31, 2004 | 517 | -56 | -9.77% |
| Dec 31, 2003 | 573 | 23 | 4.18% |
| Dec 31, 2002 | 550 | -21 | -3.68% |
| Dec 31, 2001 | 571 | 214 | 59.94% |
| Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EXEL News
- 2 days ago - Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 - Business Wire
- 4 days ago - 2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
- 25 days ago - Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 4 weeks ago - Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still - Seeking Alpha
- 4 weeks ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November - Business Wire
- 4 weeks ago - Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Business Wire
- 6 weeks ago - Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Business Wire